"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.
Thursday 24 December 2015
Regulation over Markets (or More Regulation on Regulation): California’s Initiative on Pharmaceutical Pricing
In California, there are basically at least two ways to
create a law. The first is the
traditional route through the legislature with the Governor’s signature. The second is through the initiative process. Essentially, an initiative
proposal with a certain number of voter signatures can be added to a ballot
that the electorate will vote on—think direct democracy. This process allows a bypass around the
legislature and the Governor, and allows voters to, for the most part, enact
laws. According to the Sacramento Bee,
the California Drug Price Relief Act has garnered enough signatures to be
placed on the November ballot. The Act
will require that the State (so eventually retirees, prisoners, low income folks etc) receive the same price for pharmaceuticals that
will be paid by the U.S. Department of Veterans Affairs. The article reports that proponents of the
Act state that this will lead to significantly lower prices for pharmaceuticals
and cost savings for the state government.
The pharmaceutical industry has raised a significant amount of money to
oppose the measure. However, even
without a lot of money to support it, I think the pharmaceutical industry will
lose on this. Given the level of current
poor press about pharmaceutical pricing from the recent concern about generic pricing to the pricing for Myriad’s breast cancer screening test (here), I don’t think there is much public sympathy for the pharmaceutical
industry right now. Also, an argument that "we will raise the prices on veterans" is--not surprisingly--going to go over very badly. Interestingly, the
article notes that there is a chance that the pharmaceutical industry could
reach a deal with the proponents of the initiative to withdraw the initiative
for concessions on a negotiated bill at the state legislature. That may be the pharmaceutical industry’s
best option at this point.
No comments:
Post a Comment